Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virology

Influence of Hepatitis B Virus X and Core Promoter Mutations on Hepatocellular Carcinoma among Patients Infected with Subgenotype C2

Noboru Shinkai, Yasuhito Tanaka, Kiyoaki Ito, Motokazu Mukaide, Izumi Hasegawa, Yasuhiro Asahina, Namiki Izumi, Hiroshi Yatsuhashi, Etsuro Orito, Takashi Joh, Masashi Mizokami
Noboru Shinkai
1Departments of Clinical Molecular Informative Medicine
2Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhito Tanaka
1Departments of Clinical Molecular Informative Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiyoaki Ito
2Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Motokazu Mukaide
1Departments of Clinical Molecular Informative Medicine
3SRL Inc., 51 Komiya, Hachiouji, Tokyo 192-8535
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izumi Hasegawa
4Department of Gastroenterology, Chukyo Hospital, Nagoya 457-8510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhiro Asahina
5Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo 180-8610
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Namiki Izumi
5Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo 180-8610
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Yatsuhashi
6Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Oomura, Nagasaki 856-8562, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etsuro Orito
2Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Joh
2Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masashi Mizokami
1Departments of Clinical Molecular Informative Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mizokami@med.nagoya-cu.ac.jp
DOI: 10.1128/JCM.00411-07
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Hepatitis B virus (HBV) genotypes/subgenotypes and their related mutations in the HBV genome have been reported to be associated with hepatocellular carcinoma (HCC). To determine the HCC-associated mutations of the HBV genome in the entire X, core promoter, and precore/core regions, a cross-sectional control study was conducted comparing 80 Japanese patients infected with HBV C2 and suffering from HCC with 80 age-, sex-, and hepatitis B e antigen (HBeAg) status-matched patients without HCC (non-HCC group). Each HBeAg-positive group (31 with HCC; 29 without HCC) and HBeAg-negative group (49 with HCC; 51 without HCC) was also matched with respect to age and sex. The C1479, T1485, H1499, A1613, T1653, V1753, T1762/A1764, and A1896 mutations were frequent in this population. The prevalences of the T1653 mutation in the box α region and the V1753 and T1762/A1764 mutations in the basal core promoter region were significantly higher in the HCC group than in the non-HCC group (56% versus 30%, 50% versus 24%, and 91% versus 73% [P = 0.0013, P = 0.0010, and P = 0.0035, respectively]). The platelet count was significantly lower for the HCC group than for the non-HCC group (10.7 × 104 ± 5.1 × 104 versus 17.3 × 104 ± 5.1 × 104 platelets/mm3 [P < 0.0001]). Regardless of HBeAg status, the prevalence of the T1653 mutation was higher in the HCC group (52% versus 24% [P = 0.036] for HBeAg-positive patients and 59% versus 33% [P = 0.029] for HBeAg-negative patients). In the multivariate analysis, the presence of T1653, the presence of V1753, and a platelet count of ≤10 × 104/mm3 were independent predictive factors for HCC (odds ratios [95% confidence intervals], 4.37 [1.53 to 12.48], 7.98 [2.54 to 25.10], and 24.39 [8.11 to 73.33], respectively). Regardless of HBeAg status, the T1653 mutation increases the risk of HCC in Japanese patients with HBV/C2.

Hepatocellular carcinoma (HCC) is the fifth most frequent cancer and the third leading cause of cancer-related death in the world, with an estimated prevalence of >500,000 cases worldwide per year (36). It is accepted that hepatitis B virus (HBV) has carcinogenic potential in humans. HBV has been classified into eight major genotypes (A to H) by using the complete nucleotide sequence of the viral genome (34). HBV genotypes have distinct geographical distributions and correlate with the severity of liver disease (17, 18). Genotypes B and C are prevalent in Asia, and genotype C causes more-serious liver disease than genotype B (5, 35). There are two subtypes (subgenotypes) of genotype B with distinct geographical distributions, provisionally designated Ba (“a” stands for Asia) and Bj (“j” stands for Japan) (43), and clinical differences between patients infected with HBV/Ba and HBV/Bj are becoming clear (1, 42). Recently, a phylogenetic analysis revealed two major groups within genotype C: one for strains from Southeast Asia, including Vietnam, Myanmar, Thailand, and Hong Kong (named HBV/C1), and another for strains from (Far) East Asia, including Japan and China (named HBV/C2) (6, 12, 47). Chan et al. (6) designated the two subgenotypes HBV/Cs, for Southeast Asia, and HBV/Ce, for (Far) East Asia; they not only have different geographic distributions but also different nucleotide sequences in the precore region (6, 47).

Several mutations in the HBV genome have been reported to occur during the course of persistent viral infection, and there has been increasing evidence of an association between molecular alteration and the development of HCC in patients with HBV infection. Mutations in the basal core promoter (BCP) region at nucleotides (nt) 1762 and 1764 (T1762/A1764) and in the precore region at nt 1896 (A1896) are associated with HBV e antigen (HBeAg) seroconversion and persistent viral replication. It is noteworthy that both BCP and precore mutations are often found in patients with advanced liver disease (e.g., HCC) (2, 3, 16, 19, 23, 25, 38). The T1762/A1764 mutations alter HBeAg production at the transcriptional level, and the A1896 mutation in the precore region terminates the translation of precursor protein, abrogates HBeAg production, and results in seroconversion. The T1653 mutation in the box α region has been reported to increase the risk of HCC in HBeAg-negative patients infected with HBV/C (14, 44). As well, specific mutations in the enhancer II/core promoter of HBV were differently associated with HCC in the context of HBeAg status among HBV/C1/Cs and HBV/C2/Ce carriers (46). There have been many studies involving viral mutations associated with clinical features, but most previous studies have either ignored age, sex, HBeAg status, and HBV genotype/subgenotype or have examined relatively short regions.

Here we performed a cross-sectional control study of 160 age-, sex-, and HBeAg status-matched Japanese patients infected with HBV/C2 to determine the HCC-associated mutations of the HBV genome in the entire X, core promoter, and precore plus core regions.

MATERIALS AND METHODS

Serum samples.A total of 160 serum samples were obtained from chronic HBV C2/Ce carriers who visited the Nagoya City University Hospital, Musashino Red Cross Hospital, or National Hospital Organization Nagasaki Medical Center in Japan. Of these, 140 samples were newly obtained and 20 samples were previously used (14). The study protocol conformed to the 1975 Declaration of Helsinki and was approved by the ethics committees of the institutions listed above, and informed consent was obtained from each carrier. None of the patients had a history of hepatitis C virus coinfection. In Japan, because a main transmission route of HBV is vertical, the duration of HBsAg carriage of all or most patients would correspond with their age. Hassan et al. reported that heavy alcohol consumption (>80 g ethanol per day) contributes to the majority of HCC cases (10). Heavy drinking is less prevalent in Japan; 3 of 80 patients with HCC are heavy alcohol drinkers, and 2 of 80 patients without HCC are heavy alcohol drinkers, indicating that no significant difference in heavy alcohol consumption was found in this population.

Serological assays for HBV markers.HBeAg and anti-HBe were detected by a chemiluminescent enzyme immunoassay (Lumipulse f; FUJIREBIO Inc., Tokyo, Japan).

Amplification and sequencing of the entire X, core promoter, and precore plus core regions.Nucleic acids were extracted from 100 μl of serum using a QIAamp DNA blood minikit (QIAGEN Inc., Hilden, Germany). HBV genes (665 bp) of the entire X, core promoter, precore, and core regions were amplified by PCR with heminested primers. The first-round PCR was performed with sense primer HBX1360F (TACACCTCCTTYCCATGGCTGCT) and antisense primer HB7R-2. The second-round PCR was performed with two sets of sense primers and antisense primers. One set comprised HBX1360 (sense) and Ia1 (antisense), and the second set comprised HB7F-2 (sense) and HB7R-2 (antisense) (Table 1). Thereafter, the PCR products were sequenced directly with a Prism BigDye Terminator cycle sequencing kit (Applied Biosystems) using an ABI 3100 DNA automated sequencer (Applied Biosystems). The sequences covered the entire X region, the enhancer II/core promoter (Fig. 1), and the precore genes, which are associated with HBeAg production, viral replication, and disease progression.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

C1653T, T1753V (where V stands for “not T”), and A1762T/G1764A mutations in the X region, including the enhancer II/core promoter region.

View this table:
  • View inline
  • View popup
TABLE 1.

Positions and sequences of primers used for PCR amplification and sequencing

Case-control study.According to the Gut guidelines for diagnosis of HCC (39), 80 patients received a diagnosis of HCC on the basis of results of abdominal ultrasonography, angiography, computerized tomography, or magnetic resonance imaging, as well as elevated serum α-fetoprotein levels (≥400 ng/ml). We did pathological examinations of 25 of 80 patients with HCC. For a case-control study on age-, sex-, and HBeAg status-matched subjects, another 80 patients without HCC were compared. Among the non-HCC group, 24 patients were asymptomatic carriers and 56 had chronic hepatitis.

Statistical evaluation.Data were expressed as means ± standard deviations (SD). Statistical analyses were performed using a χ2 test and Fisher's exact test for categorical variables and Mann-Whitney's U test or one-way analysis of variance for continuous variables, as appropriate. In multivariate analysis, we used 40 U of alanine aminotransferase (ALT)/liter as the cutoff. An HBV DNA level of 5 log genome equivalents (LGE)/ml and a platelet count of 10 × 104/mm3 were assessed as cutoff values, because these were used as predictors for disease progression (13, 21, 26-28, 30). Multivariate analysis with logistic regression was used to determine the independent factors associated with HCC. Differences were considered significant for P values less than 0.05. The statistical analysis software used was Stata software, version 8.0 (Stata Corp.).

Nucleotide sequence accession numbers.The sequences reported in this paper have been deposited in the GenBank/DDBJ/EMBL databases (accession numbers AB307808 to AB307967).

RESULTS

When we examined HBV DNA sequences in the entire X region as well as the enhancer II/core promoter and precore regions, C1479, T1485, H1499, A1613, T1653, V1753, T1762/A1764, and A1896 mutations were frequent in our population. Table 2 compares ALT levels, HBV DNA levels, and platelet counts, as well as mutations in the X region, box α (enhancer II), the core promoter (Fig. 1), and the precore region, among 80 patients with HCC (HCC group) and 80 patients without HCC (non-HCC group), matched for age, sex, and HBeAg status, in a case-control study. The platelet count was significantly lower for the HCC group than for the non-HCC group (10.7 × 104 ± 5.1 × 104 versus 17.3 × 104 ± 5.1 × 104 platelets/mm3; P < 0.0001). The frequencies of the T1653 mutation in the box α region and the V1753 and T1762/A1764 mutations in the BCP region were significantly higher for the HCC group than for the non-HCC group (56% versus 30%, 50% versus 24%, and 91% versus 73%; P = 0.0013, P = 0.0010, and P = 0.0035, respectively). No other significant mutations were observed in this study. Table 3 compares ALT levels and HBV DNA levels, as well as mutations in the X region, box α (enhancer II), the core promoter, and the precore region, among 60 HBeAg-positive patients (29 non-HCC and 31 HCC) matched for age and sex in a case-control study. Among HBeAg-positive patients, the platelet count was significantly lower for the HCC group than for the non-HCC group (10.6 × 104 ± 6.0 × 104 versus 13.5 × 104 ± 5.3 × 104 platelets/mm3; P = 0.0062). The frequency of the T1653 mutation in the box α region was significantly higher for the HCC group than for the non-HCC group (52% versus 24%; P = 0.036) (Table 3). Among 100 HBeAg-negative patients (51 non-HCC and 49 HCC) matched for age and sex in a case-control study, the platelet count was significantly lower for the HCC group than for the non-HCC group (11 × 104 ± 4.5 × 104 versus 19 × 104 ± 3.5 × 104 platelets/mm3; P < 0.0001), and the frequencies of the T1653 mutation in the box α region and the V1753 and T1762/A1764 mutations in the BCP region were significantly higher for the HCC group than for the non-HCC group (59% versus 33%, 61% versus 27%, and 90% versus 69%; P = 0.016, P = 0.0012, and P < 0.0001, respectively) (Table 4).

View this table:
  • View inline
  • View popup
TABLE 2.

Clinical and virologic characteristics of patients infected with HBV subgenotype C2/Ce who were matched for age, sex, and HBeAg status

View this table:
  • View inline
  • View popup
TABLE 3.

Clinical and virologic characteristics of patients infected with HBV subgenotype C2/Ce who were matched for age and were positive for HBeAg

View this table:
  • View inline
  • View popup
TABLE 4.

Clinical and virologic characteristics of patients infected with HBV subgenotype C2/Ce who were matched for age and were HBeAg negative

In the multivariate analysis among all 160 patients, the presence of T1653, the presence of V1753, and a platelet count of ≤10 × 104/mm3 were independent predictive factors for HCC (odds ratios [95% confidence intervals], 4.37 [1.53 to 12.48], 7.98 [2.54 to 25.10], and 4.39 [8.11 to 73.33], respectively) (Table 5). The presence of H1499 was identified as a significant negative factor for HCC (odds ratio, 0.243 [95% confidence interval, 0.078 to 0.76]).

View this table:
  • View inline
  • View popup
TABLE 5.

Multivariate analysis of variables with independent predictive value for HCC among a group of 160 patients with HBV infection

DISCUSSION

Many studies have reported that the clinical course of chronic HBV infection may be modified by several specific HBV mutations (7, 11, 25, 49), although the significance of such specific mutations in patients with chronic hepatitis B remains controversial. Since the viral mutations might be influenced by age, sex, HBeAg status, and HBV genotype/subgenotype, in this study we investigated sequences bearing the entire X region as well as enhancer II, BCP, and precore/core regions in order to find the specific mutations associated with HCC by comparing matched control groups (HCC versus non-HCC).

The most significant result in this study was that the presence of T1653 and the presence of V1753 were independent predictive factors for HCC in the multivariate analyses. The T1653 mutation was first found in fulminant hepatitis patients (15, 33, 48) and in cases of chronic hepatitis with acute exacerbation (32). Some studies reported that the T1653 or V1753 mutation was associated with HCC (14, 44-46). Poussin et al. also reported that the T1653 mutation was found in HCC (tumor) lesions from two patients, but interestingly, wild-type 1653 was found in nontumor lesions from the same patients (37). T1653 is located in box α, which is a strong activation element of both enhancer II and the core promoter (50), and the α box elements (nt 1646 to 1668) individually stimulate promoter activity more than 100-fold (50). The T1653 mutation converts the box α binding site for C/EBP and related factors (29, 50) into the perfect palindromic sequence 1648-TCTTATATAAGA, which might enhance binding affinity and enhancer II/core promoter activity. Hence, the T1653 mutation could influence HBeAg production and viral replication through BCP activity. Although a number of studies have reported the role of the BCP mutations in viral features, the exact mechanism of HCC development still remains unclear, particularly with respect to the effect of the mutation in the X protein. In this study, the T1762/A1764 mutations were frequent in both the non-HCC and HCC groups. The T1762/A1764 mutations had been found to be highly frequent in older HBV/C carriers (≥50 years) regardless of clinical status (14); however, these results do not contradict the possibility that T1762/A1764 is associated with hepatocarcinogenesis, because the poor prognosis of HBV/C compared to HBV/B (Ba and Bj) correlates with the high prevalence of T1762/A1764 (16). Study of a prospective cohort of 1,638 high-risk individuals in Qidong (China) showed that T1762/A1764 mutation was detected in 8 of the 15 HCC cases (53.3%) before HCC development (20), suggesting that the T1762/A1764 double mutation indicates a high potential risk for hepatocarcinogenesis. The T1653 or V1753 mutation, in addition to the T1762/A1764 mutations, may be one of the promoters of HCC development.

Several functional analyses had been already reported; Günther et al. (9) analyzed T1653, C1753, T1762, and A1764 mutations (genotype D; accession number AF043594) in the context of an in vitro study involving wild-type HBV, and they reported that precore mRNA and HBeAg secretion were reduced, but the amount of progeny virus DNA in the cells and in the culture medium increased only marginally (if at all), as determined by Southern blot analysis. Lin et al. (24) analyzed HBV replicative efficiency in vitro. HBV isolated from HCC lesions included T1653, V1753, T1762, A1764, and A1896 mutations (genotype C2; accession number AF182804). An HBV isolate from the same patient's serum 4 years before HCC diagnosis included T1762, A1764, and A1896 mutations (genotype C2; AF182802). The clone from HCC showed higher replicative efficiency than the clone before HCC development (AF182802) by Southern blot analysis. However, considering that the mutant type includes not only T1653, C1753, T1762, and A1764 mutations but also other mutations, it is possible that some other mutation influenced the results in the earlier study. Further functional analyses of HBV/C strains with the T1653 mutation are needed in vitro and in vivo.

HBx, the nonstructural regulatory protein of HBV, has been strongly associated with the development of liver cancer in some HBx-transgenic mouse strains or with increased progression to liver cancer in other toxin-exposed HBx-transgenic mouse strains (reviewed in reference 4). Many functions have been ascribed to HBx, but the precise molecular mechanism(s) responsible for its activities, and how these activities affect viral replication and possibly liver cell transformation, remains poorly defined. The T1653 mutation resulted in a histidine-to-tyrosine amino acid substitution at codon 94 of the X protein, which is the center of the immunodominant antigenic domain of amino acids (aa) 85 to 110 mapped by Stemler et al. (41). Sirma et al. (40) reported that wild-type HBx inhibited the clonal outgrowth of cells and induced apoptosis but that the mutants (same sample as in reference 37), which include the T1653 mutation derived from HCC, did not. Indeed, codon 94 (nt 1653 to 1655) is within the function domain of the X protein, which has been reported to play a central role in transactivation (22). Cong et al. (8) also reported that one of the activation domain of X (aa 90 to 122) is required for binding to XAP3 (protein kinase C-binding protein). Protein kinase C is a large family of phospholipid-dependent kinases involved in cell growth, differentiation, and carcinogenesis. It is of interest whether the T1653 mutation affects the protein-protein interactions between the X protein and XAP3. The V1753 mutation and the T1762/A1764 double mutation resulted in an isoleucine-to-asparagine/serine/threonine substitution at codon 127, a lysine-to-methionine substitution at codon 130, and a valine-to-isoleucine substitution at codon 131, respectively. These amino acid changes in the X region may also affect the function of the X protein. The occurrence of multiple mutations may represent a strategy of HBV to escape immune surveillance and thus contribute to the process of multiple steps in hepatocarcinogenesis.

With regard to other X amino acid substitutions that might be associated with HCC, Yeh et al. reported that a serine-to-alanine amino acid substitution at codon 31 (a T-to-G mutation at nt 1464) was more frequent in an HCC group than in a chronic hepatitis group (49), but the substitution at codon 31 was found for only two HCC patients (and for no patients in the non-HCC group) in the present study. The discrepancy might depend on different HBV genotypes/subgenotypes between Japan and Taiwan. Very recently, Muroyama et al. reported that a serine-to-alanine amino acid substitution at codon 38 (a C-to-T mutation at nt 1485) was more frequent in an HCC group than in a chronic hepatitis group (31). Indeed, the T1485 mutation was frequent in this study, but no significant difference between the HCC and non-HCC groups was observed. On the other hand, the H1499 mutation was a significant negative factor in the multivariate analysis, even though it was not significant in the univariate analysis. The H1499 mutation does not result in an amino acid substitution in the X protein, and a previous report by Takahashi et al. showed that the frequency of the H1499 mutation was 73% among 40 HCC patients (44). The frequency was similar to that of the non-HCC group (71%) in this study; thus, the clinical significance of the H1499 mutation remains unclear.

Finally, among HBeAg-positive patients, the T1653 and T1762/A1764 mutations or the V1753 and T1762/A1764 mutations were frequent in the HCC group (sensitivity, 69%; specificity, 72%). Also among HBe-negative patients, the T1653 and T1762/A1764 mutations or the V1753 and T1762/A1764 mutations were frequent in the HCC group (sensitivity, 67%; specificity, 81%). Hence, we would predict the groups at high risk for HCC by the combination of enhancer II/core promoter mutations with X amino acid substitutions as well as by HBV genotypes/subgenotypes. Further prospective studies in countries where HBV genotype C is endemic are required to confirm whether the accumulation of these mutations causes liver disease progression.

ACKNOWLEDGMENTS

This work was supported by a grant-in-aid for Scientific Research C from the Ministry of Education, Culture, Sports, Science, and Technology (18590741), a grant-in-aid from the Ministry of Health, Labor, and Welfare of Japan (H16-kanen-3), the Toyoaki Foundation, and the Foundation for Promotion of Cancer Research in Japan.

We declare no conflict of interest.

FOOTNOTES

    • Received 22 February 2007.
    • Returned for modification 30 April 2007.
    • Accepted 23 June 2007.
  • Copyright © 2007 American Society for Microbiology

REFERENCES

  1. 1.↵
    Akuta, N., F. Suzuki, M. Kobayashi, A. Tsubota, Y. Suzuki, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, and H. Kumada. 2003. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol.38:315-321.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Baptista, M., A. Kramvis, and M. C. Kew. 1999. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology29:946-953.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Blackberg, J., and K. Kidd-Ljunggren. 2003. Mutations within the hepatitis B virus genome among chronic hepatitis B patients with hepatocellular carcinoma. J. Med. Virol.71:18-23.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Bouchard, M. J., and R. J. Schneider. 2004. The enigmatic X gene of hepatitis B virus. J. Virol.78:12725-12734.
    OpenUrlFREE Full Text
  5. 5.↵
    Chan, H. L., A. Y. Hui, M. L. Wong, A. M. Tse, L. C. Hung, V. W. Wong, and J. J. Sung. 2004. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut53:1494-1498.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Chan, H. L., S. K. Tsui, C. H. Tse, E. Y. Ng, T. C. Au, L. Yuen, A. Bartholomeusz, K. S. Leung, K. H. Lee, S. Locarnini, and J. J. Sung. 2005. Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J. Infect. Dis.191:2022-2032.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Chu, C. M., C. T. Yeh, C. S. Lee, I. S. Sheen, and Y. F. Liaw. 2002. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J. Clin. Microbiol.40:16-21.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Cong, Y. S., Y. L. Yao, W. M. Yang, N. Kuzhandaivelu, and E. Seto. 1997. The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein. J. Biol. Chem.272:16482-16489.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Günther, S., N. Piwon, and H. Will. 1998. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653)→T, A(1762)→T and G(1764)→A mutations in the core promoter. J. Gen. Virol.79:375-380.
    OpenUrlPubMedWeb of Science
  10. 10.↵
    Hassan, M. M., L. Y. Hwang, C. J. Hatten, M. Swaim, D. Li, J. L. Abbruzzese, P. Beasley, and Y. Z. Patt. 2002. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology36:1206-1213.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Huy, T. T., H. Ushijima, V. X. Quang, T. T. Ngoc, S. Hayashi, T. Sata, and K. Abe. 2004. Characteristics of core promoter and precore stop codon mutants of hepatitis B virus in Vietnam. J. Med. Virol.74:228-236.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Huy, T. T., H. Ushijima, V. X. Quang, K. M. Win, P. Luengrojanakul, K. Kikuchi, T. Sata, and K. Abe. 2004. Genotype C of hepatitis B virus can be classified into at least two subgroups. J. Gen. Virol.85:283-292.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Ikeda, K., Y. Arase, S. Saitoh, M. Kobayashi, T. Someya, T. Hosaka, N. Akuta, Y. Suzuki, F. Suzuki, H. Sezaki, H. Kumada, A. Tanaka, and H. Harada. 2006. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J. Hepatol.44:1089-1097.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Ito, K., Y. Tanaka, E. Orito, M. Sugiyama, K. Fujiwara, F. Sugauchi, T. Kato, H. Tokita, N. Izumi, M. Kato, M. F. Yuen, C. L. Lai, R. G. Gish, R. Ueda, and M. Mizokami. 2006. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin. Infect. Dis.42:1-7.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Kaneko, M., T. Uchida, M. Moriyama, Y. Arakawa, T. Shikata, K. Gotoh, and S. Mima. 1995. Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. J. Med. Virol.47:204-208.
    OpenUrlPubMed
  16. 16.↵
    Kao, J. H., P. J. Chen, M. Y. Lai, and D. S. Chen. 2003. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology124:327-334.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Kidd-Ljunggren, K., Y. Miyakawa, and A. H. Kidd. 2002. Genetic variability in hepatitis B viruses. J. Gen. Virol.83:1267-1280.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Kidd-Ljunggren, K., E. Myhre, and J. Blackberg. 2004. Clinical and serological variation between patients infected with different hepatitis B virus genotypes. J. Clin. Microbiol.42:5837-5841.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Kobayashi, M., Y. Arase, K. Ikeda, A. Tsubota, Y. Suzuki, S. Saitoh, M. Kobayashi, F. Suzuki, N. Akuta, T. Hosaka, T. Someya, M. Matsuda, J. Sato, K. Takagi, Y. Miyakawa, and H. Kumada. 2003. Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection. Intervirology46:157-163.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Kuang, S. Y., P. E. Jackson, J. B. Wang, P. X. Lu, A. Munoz, G. S. Qian, T. W. Kensler, and J. D. Groopman. 2004. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc. Natl. Acad. Sci. USA101:3575-3580.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Kubo, S., H. Tanaka, T. Shuto, S. Takemura, T. Yamamoto, T. Uenishi, S. Tanaka, M. Ogawa, K. Sakabe, K. Yamazaki, and K. Hirohashi. 2004. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol. Res.30:221-225.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Kumar, V., N. Jayasuryan, and R. Kumar. 1996. A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. Proc. Natl. Acad. Sci. USA93:5647-5652.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Laskus, T., J. Rakela, M. J. Nowicki, and D. H. Persing. 1995. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology109:1618-1623.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Lin, X., G. S. Qian, P. X. Lu, L. Wu, and Y. M. Wen. 2001. Full-length genomic analysis of hepatitis B virus isolates in a patient progressing from hepatitis to hepatocellular carcinoma. J. Med. Virol.64:299-304.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Lindh, M., C. Gustavson, K. Mardberg, G. Norkrans, A. P. Dhillon, and P. Horal. 1998. Mutation of nucleotide 1,762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers. J. Med. Virol.55:185-190.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Lok, A. S., E. J. Heathcote, and J. H. Hoofnagle. 2001. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology120:1828-1853.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.
    Lok, A. S., and B. J. McMahon. 2001. Chronic hepatitis B. Hepatology34:1225-1241.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    Lok, A. S., and B. J. McMahon. 2004. Chronic hepatitis B: update of recommendations. Hepatology39:857-861.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    López-Cabrera, M., J. Letovsky, K. Q. Hu, and A. Siddiqui. 1990. Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: trans-activation and repression by CCAAT/enhancer binding protein. Proc. Natl. Acad. Sci. USA87:5069-5073.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Murata, K., K. Sugimoto, K. Shiraki, and T. Nakano. 2005. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection. World J. Gastroenterol.11:6848-6852.
    OpenUrlPubMed
  31. 31.↵
    Muroyama, R., N. Kato, H. Yoshida, M. Otsuka, M. Moriyama, Y. Wang, R. X. Shao, N. Dharel, Y. Tanaka, M. Ohta, R. Tateishi, S. Shiina, M. Tatsukawa, K. Fukai, F. Imazeki, O. Yokosuka, Y. Shiratori, and M. Omata. 2006. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J. Hepatol.45:805-812.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Nishizono, A., K. Kohno, Y. Takita-Sonoda, M. Hiraga, H. Terao, T. Fujioka, M. Nasu, and K. Mifune. 1997. Sequential analyses of the mutations in the core upstream and precore regions of hepatitis B virus genome in anti-HBe positive-carriers developing acute exacerbation. J. Med. Virol.53:266-272.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    Ogata, N., R. H. Miller, K. G. Ishak, and R. H. Purcell. 1993. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology194:263-276.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    Okamoto, H., F. Tsuda, H. Sakugawa, R. I. Sastrosoewignjo, M. Imai, Y. Miyakawa, and M. Mayumi. 1988. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol.69:2575-2583.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    Orito, E., M. Mizokami, H. Sakugawa, K. Michitaka, K. Ishikawa, T. Ichida, T. Okanoue, H. Yotsuyanagi, S. Iino, et al. 2001. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology33:218-223.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    Parkin, D. M. 2004. International variation. Oncogene23:6329-6340.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    Poussin, K., H. Dienes, H. Sirma, S. Urban, M. Beaugrand, D. Franco, P. Schirmacher, C. Brechot, and P. Paterlini Brechot. 1999. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int. J. Cancer80:497-505.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    Raimondo, G., R. Schneider, M. Stemler, V. Smedile, G. Rodino, and H. Will. 1990. A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis. Virology179:64-68.
    OpenUrlCrossRefPubMed
  39. 39.↵
    Ryder, S. D. 2003. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut52(Suppl. 3):iii, 1-8.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    Sirma, H., C. Giannini, K. Poussin, P. Paterlini, D. Kremsdorf, and C. Brechot. 1999. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene18:4848-4859.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    Stemler, M., T. Weimer, Z. X. Tu, D. F. Wan, M. Levrero, C. Jung, G. R. Pape, and H. Will. 1990. Mapping of B-cell epitopes of the human hepatitis B virus X protein. J. Virol.64:2802-2809.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    Sugauchi, F., E. Orito, T. Ichida, H. Kato, H. Sakugawa, S. Kakumu, T. Ishida, A. Chutaputti, C. L. Lai, R. G. Gish, R. Ueda, Y. Miyakawa, and M. Mizokami. 2003. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology124:925-932.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    Sugauchi, F., E. Orito, T. Ichida, H. Kato, H. Sakugawa, S. Kakumu, T. Ishida, A. Chutaputti, C. L. Lai, R. Ueda, Y. Miyakawa, and M. Mizokami. 2002. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J. Virol.76:5985-5992.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    Takahashi, K., Y. Akahane, K. Hino, Y. Ohta, and S. Mishiro. 1998. Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Arch. Virol.143:2313-2326.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.
    Takahashi, K., Y. Ohta, K. Kanai, Y. Akahane, Y. Iwasa, K. Hino, N. Ohno, H. Yoshizawa, and S. Mishiro. 1999. Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Arch. Virol.144:1299-1308.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    Tanaka, Y., M. Mukaide, E. Orito, M. F. Yuen, K. Ito, F. Kurbanov, F. Sugauchi, Y. Asahina, N. Izumi, M. Kato, C. L. Lai, R. Ueda, and M. Mizokami. 2006. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J. Hepatol.45:646-653.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    Tanaka, Y., E. Orito, M. F. Yuen, M. Mukaide, F. Sugauchi, K. Ito, A. Ozasa, T. Sakamoto, F. Kurbanov, C. L. Lai, and M. Mizokami. 2005. Two subtypes (subgenotypes) of hepatitis B virus genotype C: a novel subtyping assay based on restriction fragment length polymorphism. Hepatol. Res.33:216-224.
    OpenUrlPubMedWeb of Science
  48. 48.↵
    Uchida, T., T. Saitoh, and H. Shinzawa. 1997. Mutations of the X region of hepatitis B virus and their clinical implications. Pathol. Int.47:183-193.
    OpenUrlPubMed
  49. 49.↵
    Yeh, C. T., C. H. Shen, D. I. Tai, C. M. Chu, and Y. F. Liaw. 2000. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene19:5213-5220.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    Yuh, C. H., Y. L. Chang, and L. P. Ting. 1992. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J. Virol.66:4073-4084.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Influence of Hepatitis B Virus X and Core Promoter Mutations on Hepatocellular Carcinoma among Patients Infected with Subgenotype C2
Noboru Shinkai, Yasuhito Tanaka, Kiyoaki Ito, Motokazu Mukaide, Izumi Hasegawa, Yasuhiro Asahina, Namiki Izumi, Hiroshi Yatsuhashi, Etsuro Orito, Takashi Joh, Masashi Mizokami
Journal of Clinical Microbiology Oct 2007, 45 (10) 3191-3197; DOI: 10.1128/JCM.00411-07

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Influence of Hepatitis B Virus X and Core Promoter Mutations on Hepatocellular Carcinoma among Patients Infected with Subgenotype C2
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Influence of Hepatitis B Virus X and Core Promoter Mutations on Hepatocellular Carcinoma among Patients Infected with Subgenotype C2
Noboru Shinkai, Yasuhito Tanaka, Kiyoaki Ito, Motokazu Mukaide, Izumi Hasegawa, Yasuhiro Asahina, Namiki Izumi, Hiroshi Yatsuhashi, Etsuro Orito, Takashi Joh, Masashi Mizokami
Journal of Clinical Microbiology Oct 2007, 45 (10) 3191-3197; DOI: 10.1128/JCM.00411-07
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Carcinoma, Hepatocellular
Hepatitis B
hepatitis B virus
Liver Neoplasms
mutation
Promoter Regions, Genetic
Trans-Activators
Viral Core Proteins

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X